Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
CRF-Skirball Center for Innovation, Columbia University Medical Center, New York, New York, USA.
J Am Coll Cardiol. 2021 Jun 22;77(24):3058-3078. doi: 10.1016/j.jacc.2021.04.051.
Mitral regurgitation (MR) is the most prevalent valvular heart disease and, when left untreated, it confers a poorer prognosis. Catheter-based repair therapies face some limitations like their applicability on challenging anatomies and the potential recurrence of significant MR over time. Transcatheter mitral valve replacement (TMVR) has emerged as a less invasive approach potentially overcoming some of the current limitations associated with transcatheter mitral valve repair. Several devices are under clinical investigation, and a growing number of systems allow for a fully percutaneous transfemoral approach. In this review, the authors aimed to delineate the main challenges faced by the TMVR field, to highlight the key aspects for procedural planning, and to describe the clinical results of the TMVR systems under clinical investigation. Finally, they also discuss what the future perspectives are for this emerging field.
二尖瓣反流(MR)是最常见的瓣膜性心脏病,如果不进行治疗,其预后较差。基于导管的修复疗法面临一些局限性,例如它们在具有挑战性的解剖结构上的适用性和随着时间的推移,显著 MR 复发的可能性。经导管二尖瓣置换术(TMVR)作为一种微创方法,有可能克服与经导管二尖瓣修复相关的一些当前局限性。有几种设备正在临床研究中,越来越多的系统允许经股动脉完全经皮入路。在这篇综述中,作者旨在阐明 TMVR 领域面临的主要挑战,强调手术规划的关键方面,并描述正在临床研究中的 TMVR 系统的临床结果。最后,他们还讨论了这一新兴领域的未来前景。